GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) has announced its upcoming participation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The company's management will deliver a presentation on Thursday, November 21 at 11:00 a.m. ET. The event will be accessible via live and replay webcasts through GRAIL's investor relations website section at investors.grail.com, with recordings available for at least 30 days following the presentation.

News Market Reaction – GRAL

-0.50%

-0.50% Session move

In the trading session that priced this news, GRAL declined 0.50%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m. ET. 

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302295742.html

SOURCE GRAIL, Inc.

FAQ

When is GRAIL (GRAL) presenting at the Canaccord Genuity Forum in November 2024?

GRAIL (GRAL) will present at the Canaccord Genuity Forum on Thursday, November 21, 2024, at 11:00 a.m. ET in New York.

How can investors watch GRAIL's (GRAL) Canaccord Genuity Forum presentation?

Investors can watch the presentation through live and replay webcasts available in the investor relations section of GRAIL's website at investors.grail.com.

How long will GRAIL's (GRAL) Canaccord Genuity presentation replay be available?

The webcast replay will be archived and available for at least 30 days after the event.

What type of forum is GRAIL (GRAL) presenting at in November 2024?

GRAIL is presenting at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which focuses on medical technology and healthcare services.